Minzasolmin

Phase 2: mid-stage testing

An oral drug aimed at preventing alpha-synuclein from clumping, in a Phase 2 trial. Whether it slows Parkinson's is not yet known.

• Stage: Phase 2 (ORCHESTRA)
• Type: Disease-modifying
• Developer: UCB and Novartis
• Target: Alpha-synuclein
• How it works: A pill designed to stop the alpha-synuclein protein from misfolding and clumping inside brain cells.
• Who it's for: People with early, untreated or recently treated Parkinson's.
• Key trials: NCT04658186
• Last reviewed: 2026-06-01

What it is

Unlike antibody infusions that target alpha-synuclein from outside the cell, minzasolmin is a small molecule pill intended to interfere with the protein misfolding earlier in the process, inside the cell.

Where it stands

It has been tested in the Phase 2 ORCHESTRA trial. Results determine whether the approach moves forward.

What the data shows so far

ORCHESTRA enrolled people with early Parkinson's for roughly a year and a half, measuring change on Parkinson's rating scales. As with other disease-modifying attempts, any benefit would be a slowing of decline rather than immediate symptom relief; read-outs should be judged against the pre-specified primary endpoint, not selected subgroups.

What families should know

This is another shot at the central alpha-synuclein hypothesis, in convenient pill form. It is experimental and not shown to slow the disease.

Caveats

Unproven; a single Phase 2 study. The alpha-synuclein strategy as a whole has produced repeated disappointments, so cautious expectations are warranted.

Timeline

Most recent first.

• 2021, ORCHESTRA Phase 2 trial begins.

Sources

• ORCHESTRA on ClinicalTrials.gov

Last reviewed: 2026-06-01. Back to the Parkinson's drug pipeline